MX349321B - Terapia combinada. - Google Patents

Terapia combinada.

Info

Publication number
MX349321B
MX349321B MX2014000199A MX2014000199A MX349321B MX 349321 B MX349321 B MX 349321B MX 2014000199 A MX2014000199 A MX 2014000199A MX 2014000199 A MX2014000199 A MX 2014000199A MX 349321 B MX349321 B MX 349321B
Authority
MX
Mexico
Prior art keywords
combination therapy
individuals
cancer
minimising
progression
Prior art date
Application number
MX2014000199A
Other languages
English (en)
Other versions
MX2014000199A (es
Inventor
Alexander Barden Julian
Gidley-Baird Angus
Original Assignee
Biosceptre (Aust) Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011902623A external-priority patent/AU2011902623A0/en
Application filed by Biosceptre (Aust) Pty Ltd filed Critical Biosceptre (Aust) Pty Ltd
Publication of MX2014000199A publication Critical patent/MX2014000199A/es
Publication of MX349321B publication Critical patent/MX349321B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Abstract

La presente invención se refiere a un receptor P2X7 o un fragmento del mismo para usarse en un método para minimizar la progresión del cáncer en un individuo, en donde el individuo ha recibido un sitio no propio de unión de antígenos para el tratamiento del cáncer, en donde el fragmento de un receptor P2X7 es capaz de formar una respuesta inmunitaria a un receptor P2X7, y que incluye una secuencia de aminoácidos seleccionada del grupo que consiste en SEQ ID NO: 2, 3 y 4.
MX2014000199A 2011-07-01 2012-07-02 Terapia combinada. MX349321B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2011902623A AU2011902623A0 (en) 2011-07-01 Combination therapy
PCT/AU2012/000795 WO2013003895A1 (en) 2011-07-01 2012-07-02 Combination therapy

Publications (2)

Publication Number Publication Date
MX2014000199A MX2014000199A (es) 2014-06-11
MX349321B true MX349321B (es) 2017-07-21

Family

ID=47436374

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000199A MX349321B (es) 2011-07-01 2012-07-02 Terapia combinada.

Country Status (11)

Country Link
US (3) US9566318B2 (es)
EP (1) EP2726095B1 (es)
JP (2) JP6305920B2 (es)
CN (1) CN103702683B (es)
AU (1) AU2012278921B2 (es)
BR (1) BR112013033974A2 (es)
CA (1) CA2840251C (es)
ES (1) ES2689272T3 (es)
MX (1) MX349321B (es)
WO (1) WO2013003895A1 (es)
ZA (1) ZA201400120B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60230482D1 (de) 2001-01-17 2009-02-05 Intreat Pty Ltd Antikörper gegen nichtfunktionelle p 2 x 7 rezeptoren, diagnose und behandlung von krebs und anderen leiden
NZ583894A (en) 2007-09-14 2013-01-25 Biosceptre Int Ltd Antibodies that bind to a non atp binding p2x7 receptor
CA2729868C (en) 2008-07-04 2018-07-10 Biosceptre International Limited Anti- p2x7 peptides and epitopes
EP2966090B1 (en) 2009-08-20 2018-10-10 Biosceptre (Aust) Pty Ltd Anti p2x7 receptor antibodies and fragments thereof
ES2667003T3 (es) 2009-12-24 2018-05-09 Biosceptre (Aust) Pty Ltd Anticuerpos para receptores P2X7 oligoméricos no funcionales
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
US8846107B2 (en) 2010-12-29 2014-09-30 Ecolab Usa Inc. In situ generation of peroxycarboxylic acids at alkaline pH, and methods of use thereof
US8889900B2 (en) 2010-12-29 2014-11-18 Ecolab Usa Inc. Sugar ester peracid on site generator and formulator
CA2840251C (en) 2011-07-01 2023-09-12 Biosceptre International Limited Combination therapy of diseases that are associated with non-functional p2x7 receptor expression
US9321664B2 (en) 2011-12-20 2016-04-26 Ecolab Usa Inc. Stable percarboxylic acid compositions and uses thereof
US11040902B2 (en) 2014-12-18 2021-06-22 Ecolab Usa Inc. Use of percarboxylic acids for scale prevention in treatment systems
JP6802166B2 (ja) 2014-12-18 2020-12-16 エコラボ ユーエスエー インコーポレイティド 多価アルコールホルマートによるペルオキシギ酸の生成
CA2971416C (en) 2014-12-18 2024-01-23 Ecolab Usa Inc. Methods for forming peroxyformic acid and uses thereof
CN109862883A (zh) * 2016-10-21 2019-06-07 生物权威（英国）有限公司 细胞毒性颗粒
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
JPH10501122A (ja) 1994-05-27 1998-02-03 グラクソ、グループ、リミテッド Ｐ▲下２ｘ▼レセプター（プリノセプターファミリー）
CA2228999A1 (en) 1995-08-09 1997-02-20 Institut National De La Sante Et De La Recherche Medicale Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
WO1997041222A1 (en) 1996-04-30 1997-11-06 Smithkline Beecham P.L.C. HUMAN P2x4 RECEPTOR SPLICE-VARIANTS
US6303338B1 (en) 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6133434A (en) 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
ES2329851T3 (es) 1998-06-01 2009-12-01 Agensys, Inc. Nuevos antigenos transmembranables expresados en canceres humano y utilizacion de los mismos.
DE19829473C2 (de) 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
EP1157038A4 (en) 1999-02-26 2005-01-19 Smithkline Beecham Corp CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17)
AUPP991199A0 (en) 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
NL1012452C2 (nl) 1999-06-28 2001-01-02 Univ Delft Tech Werkwijze voor de bereiding van eiwit-agglomeraten, eiwit-agglomeraten, een levensmiddel en een farmaceutisch preparaat die deze bevatten alsmede een inrichting voor het bereiden van eiwit-agglomeraten.
AU1339701A (en) 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
DE60230482D1 (de) 2001-01-17 2009-02-05 Intreat Pty Ltd Antikörper gegen nichtfunktionelle p 2 x 7 rezeptoren, diagnose und behandlung von krebs und anderen leiden
NZ565994A (en) * 2001-09-03 2010-02-26 Intreat Pty Ltd Antibodies to non-functional P2X7 receptor, diagnosis and treatment of cancers and other conditions
MXPA05011008A (es) 2003-04-17 2006-03-08 Affectis Pharmaceuticals Ag Medios y metodos para diagnosticar y tratar trastornos afectivos.
LT2163260T (lt) 2004-01-23 2017-06-26 Msd Italia S.R.L. Šimpanzės adenoviruso vakcinos nešikliai
US7858323B2 (en) * 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
GB0419295D0 (en) * 2004-08-31 2004-09-29 Genomica Sau Methods and compositions to prevent neuronal degeneration
EP1885376A1 (en) 2005-05-05 2008-02-13 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
EP1929305A2 (en) 2005-08-31 2008-06-11 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
JP2010505426A (ja) 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
US20100036101A1 (en) 2006-10-10 2010-02-11 Angus Gidley-Baird Antibodies against non functional p2x7 receptor
NZ583894A (en) * 2007-09-14 2013-01-25 Biosceptre Int Ltd Antibodies that bind to a non atp binding p2x7 receptor
AU2008299594B2 (en) 2007-09-14 2013-10-03 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
CA2729868C (en) 2008-07-04 2018-07-10 Biosceptre International Limited Anti- p2x7 peptides and epitopes
ES2639577T3 (es) * 2008-12-10 2017-10-27 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vacuna para la prevención de la recurrencia del cáncer de mama
EP2966090B1 (en) 2009-08-20 2018-10-10 Biosceptre (Aust) Pty Ltd Anti p2x7 receptor antibodies and fragments thereof
ES2667003T3 (es) * 2009-12-24 2018-05-09 Biosceptre (Aust) Pty Ltd Anticuerpos para receptores P2X7 oligoméricos no funcionales
US8828944B2 (en) 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
CA2840251C (en) 2011-07-01 2023-09-12 Biosceptre International Limited Combination therapy of diseases that are associated with non-functional p2x7 receptor expression

Also Published As

Publication number Publication date
CN103702683B (zh) 2017-07-04
JP6490270B2 (ja) 2019-03-27
BR112013033974A2 (pt) 2017-02-14
US9566318B2 (en) 2017-02-14
US10245308B2 (en) 2019-04-02
JP2018087249A (ja) 2018-06-07
AU2012278921A1 (en) 2014-01-16
CA2840251C (en) 2023-09-12
CN103702683A (zh) 2014-04-02
US10543262B2 (en) 2020-01-28
EP2726095A4 (en) 2015-01-07
AU2012278921B2 (en) 2016-11-10
WO2013003895A1 (en) 2013-01-10
US20170157229A1 (en) 2017-06-08
JP6305920B2 (ja) 2018-04-04
ES2689272T3 (es) 2018-11-13
MX2014000199A (es) 2014-06-11
CA2840251A1 (en) 2013-01-10
EP2726095A1 (en) 2014-05-07
US20190224290A1 (en) 2019-07-25
US20150004179A1 (en) 2015-01-01
EP2726095B1 (en) 2018-06-06
ZA201400120B (en) 2015-09-30
JP2014520759A (ja) 2014-08-25

Similar Documents

Publication Publication Date Title
MX349321B (es) Terapia combinada.
CA145237S (en) Combined cover and saucer
CA139448S (en) Stimulation device
TN2014000206A1 (en) Antibody molecules having specificity for human ox40
CA143950S (en) Pillow
CA145514S (en) Pump
CA147075S (en) Ceiling lamp
CA141065S (en) Dual c clip
TN2012000414A1 (en) Forms of rifaximin and uses thereof
CA145612S (en) Patient interface assembly
CA145611S (en) Patient interface assembly
CA139066S (en) Stimulation device
CA143981S (en) Breast pump
CA143605S (en) Bracelet
CA142744S (en) Epilator
CA147873S (en) Teapot
CA141066S (en) Dual c clip
CA145176S (en) Can
CA143665S (en) Boot
CA141191S (en) Packaging
CA141484S (en) Micro audio system
CA143997S (en) Chair
CA146512S (en) Head-guard
CA141190S (en) Packaging
CA141192S (en) Packaging

Legal Events

Date Code Title Description
FG Grant or registration